Creation of Major Development Products

「工業品の新規創出活動や産学官新領域連携、東京大学「社会連携講座」、サイントル株式会社とウェアラブルデバイスに関する共同開発契約を締結するなど、新たな価値創出を推進しています。」

「The principal R&D achievements for the consolidated fiscal year were as follows: ① Launch of Loihi Tsuboko Coin Plaster (an overseas product from the Loihi series of topical analgesic and anti-inflammatory products) ② Launch of Battlewin™ Sole Protector (an arch-support tape for the sole that reduces strain caused by standing work and prolonged walking) ③ Launch of Battlewin™ Bunion Protector (toe-support tape for painful bunions)」

「また、縫合創用ドレッシング「サージフィットTM」については、国立大学病院及び急性期病院においてその有用性が高く評価され、採用を拡大しております。」

「In the high-moisture-permeability film dressing Cathelip™ Plus series, the new Cathelip™ Plus I.V. Slit for Pediatric Use received high ratings, and adoption by new medical institutions that prioritize medical safety expanded. Net sales exceeded the same period of the previous year.」

「Launch of new products through B2C development marketing and B2B field proposals, and creation of results in new fields and product categories ・Creation and sharing of results from the deepening and evolution of core technologies, and creation of new businesses in target fields through open innovation and collaboration」

「Launch of new products through B2C development marketing and B2B field proposals, and creation of results in new fields and product categories」

「・Launch of new products through B2C development marketing and B2B field proposals, and exploration and creation of businesses in new fields and product categories ・Creation of new businesses through the deepening, evolution and sharing of core technologies, as well as open innovation and collaboration」

「・Launch of new products through B2C development marketing and B2B field proposals, and exploration and creation of businesses in new fields and product categories ・Creation of new businesses through the deepening, evolution and sharing of core technologies, as well as open innovation and collaboration」

「The principal R&D achievements for the consolidated fiscal year were as follows: ① Launch of Battlewin™ Kinesiology Tape, Extra Strength Adhesive ② Launch of Barrier Sati™ (virus-removing and disinfecting spray)」

「・Reorganization of the R&D organization to establish innovative R&D and product design ・Promotion of collaboration programs with startups」

「Achieving the early launch of new products through market-in development, and exploring and creating the next generation of major products」

「Against this backdrop, sales of the high-function emergency adhesive bandage Careleaves series exceeded the previous-year period, due to the effect of television commercials and increased cases of rough, cracked hands caused by falling temperatures and disinfection during the COVID-19 pandemic.」

「Against this backdrop, sales of the high-function emergency adhesive bandage Careleaves series were level with the previous year as sampling and promotional activities increased awareness, but sales for the field as a whole fell significantly below the previous year.」

「The principal research and development results for the fiscal year were as follows: ① launch of Hycoroll (hydrocolloid tape for skin protection in pressure-ulcer care and reinforcement of stoma wafer fixation).」

「Against this backdrop, sales of the Askabric series for total postoperative care significantly exceeded the previous year. Sales of the Caterie Plus series of highly moisture-permeable film dressings also exceeded the previous year as the value of low irritation gained acceptance.」

「The company launched a small pack containing half the number of units in the previous products, along with the adhesive elastic fabric bandage Skinergate Gachitto and the omnidirectional elastic adhesive bandage Skinergate Pitatto. Sales of existing products also exceeded the previous year.」

「The Askabric series of total postoperative care products, including the postoperative scar-care tape Atfine, which was commercialized based on the needs of medical professionals, was actively exhibited at medical conferences, leading to new hospital adoptions.」

「② Roihi Cream Felbi (Topical warming analgesic and anti-inflammatory product in a three-ball roll-on tube) Launch」

「Sales of the ultra-low-irritation surgical tape Skinergate, the film dressing Caterie Plus, and the Sesabric series of products for protection and hemostasis during injections and intravenous treatments remained firm. The Askabric series of total postoperative care products, including the postoperative scar-care tape Atfine, steadily increased the number of adoptions, and sales progressed steadily.」

「In the Roihi series of analgesic and anti-inflammatory products, the company launched Roihi Cream Felbi, a roll-on cream, the industry's first analgesic and anti-inflammatory cream in roll-on form,」

「The company focused on sales of the ultra-low-irritation surgical tape Skinergate, the film dressing Caterie Plus, and the Sesabric series of products for protection and hemostasis during injections and intravenous treatments. The Askabric series of total postoperative care products, including the postoperative scar-care tape Atfine, increased new hospital adoptions, and sales performed well.」

「The principal research and development results for the fiscal year were as follows: ① launch of W Grip (elastic self-adhesive bandage); ② launch of Therapore Tape FX Black; ③ launch of Akagire Protection Band for spot application; ④ launch of Careleaves Heal Force waterproof type for heels; ⑤ launch of clear adhesive bandages specifically for blisters.」

「The company launched Battlewin W Grip, a taping tape with new functions and an improved fit, and began sales activities.」

「The company focused on sales of the ultra-low-irritation surgical tape Skinergate, the film dressing Caterie Plus, the Sesabric series of products for puncture-site protection and hemostasis, and the Askabric series of total postoperative care products, but sales, including specially ordered products, fell below the previous year.」

「(Medical business) The principal research and development results for the fiscal year were as follows: ① launch of Fastenart (skin-closure tape); ② launch of Speel Gel (treatment for corns, calluses, and warts).」

「The company advanced sales of the ultra-low-irritation surgical tape Skinergate Spat and the high-moisture-permeability film dressing Caterie Plus, whose performance reflects requests from medical professionals. It also proposed the skin-closure tape Fastenart and the postoperative scar-healing tape Atfine under the Askabric brand for total postoperative care, and sales progressed steadily.」

「The company renewed the skin-closure tape Fastenart and, together with the postoperative scar-healing tape Atfine, focused on proposal activities for products under the new Askabric brand for total postoperative care. Sales progressed steadily.」

「The Group commercialized the ultra-low-irritation surgical tape Skinergate Spat and the film dressing Caterie Plus by incorporating the needs of medical professionals, focused on sales of these products, and launched the surgical scar-care tape Atfine in the previous fiscal year. Sales progressed steadily.」

「1) Creating major new products * Rapid development of new products closely aligned with customers and development of the market」